APOE and Alzheimer disease: Despite the heterogeneity of CAA, understanding its role is important, especially as amyloid‐beta modifying therapies may lead to an increase in CAA and with adverse vascular events in AD, with APOE status influencing outcomes (76, 77, 78, 79).